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ABSTRACT
Epidemiologic studiesQ4 show an increased risk of non‐Hodgkin lymphoma (NHL) in
patientsQ5 with autoimmune disease (AD), due to a combination of shared
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environmental factors and/or genetic factors, or a causative cascade: chronic
inflammation/antigen‐stimulation in one disease leads to another. Here we assess
shared genetic risk in genome‐wide‐association‐studies (GWAS).
Secondary analysis of GWAS of NHL subtypes (chronic lymphocytic leukemia,
diffuse large B‐cell lymphoma, follicular lymphoma, and marginal zone lymphoma)
and ADs (rheumatoid arthritis, systemic lupus erythematosus, and multiple
sclerosis). Shared genetic risk was assessed by (a) description of regional genetic of
overlap, (b) polygenic risk score (PRS), (c)"diseasome", (d)meta‐analysis.
Descriptive analysis revealed few shared genetic factors between each AD and
each NHL subtype. The PRS of ADs were not increased in NHL patients (nor
vice versa). In the diseasome, NHLs shared more genetic etiology with ADs than
solid cancers (p = .0041). A meta‐analysis (combing AD with NHL) implicated
genes of apoptosis and telomere length.
This GWAS‐based analysis four NHL subtypes and three ADs revealed few
weakly‐associated shared loci, explaining little total risk. This suggests common
genetic variation, as assessed by GWAS in these sample sizes, may not be the
primary explanation for the link between these ADs and NHLs.
KEYWORD S
autoimmune disease, genome‐wide association study, meta‐analysis, non‐Hodgkin lymphoma
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1 | INTRODUCTION
It is well established that patients with autoimmune
diseases (AD) such as rheumatoid arthritis (RA), Sjögren's
syndrome, and systemic lupus erythematosus (SLE) are at
increased risk of malignant lymphomas, that is, Hodgkin
and non‐Hodgkin lymphomas (NHL; Baecklund, Smedby,
Sutton, Askling, & Rosenquist, 2014; Thun, Linet, Cerhan,
Haiman, & Schottenfeld, 2017) (Hemminki, Försti, Sund-
quist, Sundquist, & Li, 2017). Different mechanisms may
plausibly contribute to this association. For instance, an
autoimmune reaction may involve chronic antigenic
stimulation and inflammation, which may promote lym-
phoma development through heightened B‐ or T‐cell
activation (Baecklund et al., 2014). Increased risks of
salivary gland marginal zone lymphomas (MZL) of B‐cell
origin in patients with Sjögren's syndrome and of small
intestinal T‐cell lymphomas in patients with celiac disease
support such mechanisms (Baecklund et al., 2014). AD
treatment might also contribute to the observed increased
lymphoma risk, for example, through suppression of the
immune system (Baecklund et al., 2014).
Although these mechanisms are intuitively an appeal-
ing explanation for the AD‐NHL association, the associa-
tion might also theoretically involve other risk factors
shared by the two groups of diseases. In this regard, the
current understanding of environmental risk factors
possibly shared by ADs and NHLs, such as smoking,
offers no convincing explanation for their mutual cluster-
ing (Thun et al., 2017; Deane et al., 2010; Park et al., 2009;
Belbasis, Bellou, Evangelou, Ioannidis, & Tzoulaki, 2015;
Smedby & Ponzoni, 2017; Ekström et al., 2003; Bernatsky
et al., 2013). Further, meta‐analyses of genome‐wide
association studies (GWAS) suggested genetic overlap
between SLE and diffuse large B‐cell lymphoma (DLBCL;
Bernatsky et al., 2017), and between multiple sclerosis
(MS) and Hodgkin lymphoma (Khankhanian et al., 2016)
as a partial explanation of the accumulation of those two
diseases among relatives.
Here, we use available GWAS data from three ADs,
RA, SLE, and MS, and four NHL subtypes, DLBCL,
chronic lymphocytic leukemia (CLL), follicular lympho-
ma (FL), and MZL, to explore genetic commonalities
between the two disease groups.
2 | MATERIALS AND METHODS
2.1 | MS, RA, SLE, and NHL data set
characteristics
The MS study consists of 9,772 cases and 17,376 controls
from the Wellcome Trust Case Control Consortium 2
(WTCCC2) project (International Multiple Sclerosis Genetics
Consortium, 2011; Table 1). Individuals in this data set were
of European descent and originated from 15 geographic
regions, including the USA, Australia, New Zealand, and
numerous European countries. Included in this data set were
summary‐level association results for a total of 464,434 single
nucleotide polymorphisms (SNPs). The genotyping platform
was the Illumina Human 660‐Quad platform; quality control
was performed by the original authors and a log‐additive
genetic model was used.
The RA study consists of a combined 3,921 cases and
4,079 controls of European descent from a meta‐analysis of
two datasets: WTCCC1 (Wellcome Trust Case Control
Consortium, 2007) and the epidemiological investigation of
rheumatoid arthritis (EIRA) data set (Padyukov et al., 2011;
Table 1). The combined data set (union) had summary‐level
association results for 650,312 SNPs. The genotyping plat-
form was the Illumina 300K chip; imputation and quality
control were performed by the original authors and a log‐
additive genetic model was used.
The SLE study consists of combined 7,219 cases and
15,991 controls of European descent from the Bentham
et al. (2015) multicenter study (Table 1). The study had
summary‐level association results for 623,954 SNPs. The
genotyping platform was the Illumina HumanOmni1‐
Quad BeadChip; quality control was performed by the
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original authors and a log‐additive genetic model was
used.
The NHL study consists of cases and controls from
multiple studies of four B‐Cell NHL subtypes: DLBCL
(Cerhan et al., 2014), FL (Skibola et al., 2014),
CLL (Berndt et al., 2016), and MZL (Vijai et al., 2015)
(Table 1). Individuals in this data set were also of
European descent and originated from the USA and
numerous European countries. Together, these datasets
include summary‐level association results (actual and
imputed) for a total of 9,116,853 SNPs for DLBCL,
9,116,853 SNPs for CLL, 9,078,855 SNPs for FL, and
8,478,065 SNPs for MZL.
To generate a single working data set containing
association results for each AD and each subtype of NHL,
the datasets were merged according to SNP name, giving
a final data set containing summary‐level results for a
total of approximately 460,000 overlapping SNPs for MS
and each NHL subtype, 600,000 overlapping SNPs for RA
and each NHL subtype, and 600,000 SNPs for SLE and
each NHL subtype. R and Plink statistical software were
used for all subsequent analyses (Purcell et al., 2007; R
Core Team, 2013).
2.2 | SNP‐level overlap between
diseases
For each of the 12 cross‐disease analyses, we followed a
procedure used in other meta‐analyses of complex genetic
diseases (Khankhanian et al., 2016). For example, to assess
the genetic overlap between MS and DLBCL, we first
identified SNPs that associated independently with either
disease. Then, in each disease, we grouped SNPs by
increasing significance by establishing seven association
thresholds ranging from p < 5 x 10−8 to p < 5 x 10−1. From
the collection of SNPs that reached a given threshold, we
selected only independent subsets (r2 < 0.1 in CEU),
preferentially keeping SNPs with lower p values. (The CEU
are controls of Northern and Western European ancestry
from CEPH (Center d'Etude du Polymorphism Humain) a
collection based on 1000 Genomes and HapMap genotype
data; r2 was downloaded using SNAP software.) Each subset
of SNPs for each AD was tested for association with each
NHL subtype. Association test statistics were adjusted for
multiple testing using Benjamini–Hochberg’s false discovery
rate (FDR) method based on the total number of SNPs in the
subset. An FDR< 0.05 was considered statistically significant.
The reverse process was performed to test each set of NHL
SNPs and AD risk. SNP‐level analyses were conducted for
each combination of one autoimmune disease (MS, RA, and
SLE) and one subtype of NHL (DLBCL, CLL, FL, and MZL).
2.3 | Polygenic risk scores
Polygenic risk scores (PRS) were calculated to test the
cumulative effect of SNPs associated with each AD on NHL
and vice versa. For example, for the comparison of SLE and
DLBCL, sets of top independent SNPs were chosen as
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TABLE 1 The GWAS used for the meta‐analysis
Disease Study Unique cases Unique controls Original genotyped SNPs
MS WTCCC2 (12) 9,772 17,376 465,434
RA WTCCC1 (13) and EIRA (14) 3,921 4,079 650,312
SLE Bentham study (15) 7,219 15,991 623,954
DLBCL Groupe d'Etude des Lymphomes de l'Adulte (16) 549 525 513,264
DLBCL Mayo‐DLBCL (16) 393 172 516,286
DLBCL San Francisco (16) 254 749 290,454
DLBCL Omni 2,421 5,991 607,957
CLL San Francisco 213 See SF above 290,454
CLL Omni 1,953 See Omni above 607,957
CLL Utah 326 413 559,899
FL San Francisco (SF) 210 See SF above 290,454
FL San Francisco (SF2) 119 349 599,547
FL Scandinavian lymphoma etiology (SCALE) 376 791 297,989
FL Omni (22 sites) 1,981 See Omni above 607,957
MZL Omni (22 sites) 741 See Omni above 607,957
Abbreviations: CLL, chronic lymphocytic leukemia; DLBCL, diffuse large B‐cell lymphoma; EIRA, epidemiological investigation of rheumatoid arthritis; FL,
follicular lymphoma; GWAS, genome‐wide association studies; MS, multiple sclerosis; MZL, marginal zone lymphomas; RA, rheumatoid arthritis; SLE,
systemic lupus erythematosus; SNPs, single nucleotide polymorphisms; WTCCC2, Wellcome Trust Case Control Consortium 2.
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described above. The SLE‐PRS and the DLBCL‐PRS were
calculated for each individual; the PRS is defined as the
weighted sum of the number of risk alleles at each SNP
in the set, weighted by the log odds ratio of association for
each SNP (Khankhanian et al., 2016). We assessed the
ability of the SLE‐PRS to distinguish DLBCL cases from
controls and the ability of the DLBCL‐PRS to distinguish SLE
cases from controls using the Nagelkerke R2. This analysis
was repeated for each combination of one NHL subtype
(DLBCL, FL, CLL, and MZL) and one AD (SLE, RA,
and MS).
2.4 | Meta‐Analysis
To identify novel susceptibility loci in our merged data
set, we combined summary results from each AD and
each NHL subtype in a meta‐analysis. For each pair of
diseases, for all overlapping SNPs, discovery‐level p
values and odds ratios (OR) from the AD and NHL
datasets (as provided by the authors of those original
studies) were combined using a fixed‐effects meta‐
analysis as implemented in the Plink software package.
The p‐value threshold for Cochrane's Q statistic was set
to 0.05 to screen for heterogeneity in results across
studies.
2.5 | Diseasome
To visualize the similarities between ADs and the NHL
subtypes, we built a human disease network based on disease
proximities, as previously described (Khankhanian et al.,
2016; Himmelstein, Khankhanian, Baranzini, 2015). Briefly,
proximity was calculated using a random walk with restart
over a heterogeneous network wherein diseases are con-
nected by shared genetic etiology, as determined by
databases of previously published data. Two diseases with
greater shared genetic etiology will have greater proximity
due to a larger number of connections. The mean proximity
between NHLs and ADs was compared to the mean
proximity between NHLs and solid cancers with the Fisher
test. Similarly, the mean proximity between NHL and solid
cancers was compared to the mean proximity between NHL
and all other diseases (Khankhanian et al., 2016; Himmel-
stein et al., 2015).
3 | RESULTS
3.1 | Overview
A total of 9,772 MS patients, 3,921 RA patients, 7,219 SLE
patients, 3,617 DLBCL patients, 2,492 CLL patients,
2,686 FL patients, 741 MZL patients, and 46,436 total
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FIGURE 1 Study design and data analysis procedures. For each of the 12 pairs of diseases (three ADs and four NHLs), results from
previous GWAS were used to assess genetic overlap between the two diseases. SNPs independently associated with both diseases were
identified. Genetic risk scores were evaluated for genomewide overlap. Network analysis evaluated the proximity of these diseases in the
context of other human diseases. After the evaluation of genetic overlap, we merged GWAS results for each AD‐NHL in a meta‐analysis to
discover novel genes associated with both diseases. AD, autoimmune disease; GWAS, genome‐wide association studies; NHL, non‐Hodgkin
lymphoma; SNPs, single nucleotide polymorphisms
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controls were analyzed. Figure 1 gives an overview of
study design and data analysis. For each of 12 pair‐wise
comparisons, comparing one of four NHL subtypes
against one of three ADs, the following analyses
are presented. First, we present SNPs that associated
independently with both diseases. Next, we present PRS
to assess the cumulative genome‐wide effect of AD‐
associated SNPs on NHL and of NHL‐associated SNPs on
AD. To identify susceptibility genes common to each of
12 disease pairs, a series of 12 GWAS meta‐analyses are
presented. Finally, the three ADs and the four NHL
subtypes from this study were mapped in a genetic
diseasome, a network of diseases, with other ADs, NHLs,
solid cancers, and other unrelated diseases, and relative
proximity of diseases are presented.
3.2 | SNP and HLA‐allele overlap
between ADs and NHLs
Each of the three ADs was evaluated for SNP‐level
overlap with each of the four NHLs, resulting in
12 comparisons. The comparison of SLE versus DLBCL
is detailed as an example (Table 2, Row 1). We identified
2,472 SNPs that associated with SLE at a significance
threshold of p < 5 x 10‐4. After discarding SNPs for which
linkage disequilibrium (LD) information was not
available, 1,718 SNPs remained to represent 389 inde-
pendent regions (with r2 < 0.1 as the threshold to
define independence). Of the 389 SNPs (one SNP per
independent region), two of these were significantly
associated with DLBCL (p < .05 after Benjamini–Hoch-
berg correction for 389 multiple tests). Similar results
were found when DLBCL‐associated SNPs were assessed
for association with SLE (Table 2, Row 2). Details
regarding the individual overlapping SNPs are given in
Table S1.
The analysis was repeated for other ADs and other
NHL subtypes. In each comparison, a relatively small
number of overlapping regions was identified, at most 14.
The greatest amount of overlap was observed in the
comparisons between MS and CLL and between MS and
FL; SLE had a smaller number of overlapping SNPs with
the NHL subtypes, and RA had the smallest number of
overlapping SNPs with the NHL subtypes. The differ-
ences in the amount of overlap between specific ADs
were small, although it should be noted that this analysis
was not equipped to make quantitative assertions about
the significance of the difference in overlap (as these
differences are highly dependent on other factors
including the difference in power between studies).
This analysis was repeated with the initial significance
thresholds ranging from p < 5 x 10−8 to p < 5 x 10−1;
while the results in Table 2 reflect a threshold of
p < 5 x 10−4 as an example, a similar pattern of results
held at other thresholds. Details of the SNPs comprising
this overlap are given in Table S1.
3.3 | Polygenic risk‐overlap between
diseases
To assess the extent of genetic risk overlap between AD
and NHL subtypes at the genome‐wide level (including
human leukocyte antigen (HLA) region), PRS, termed
MS‐PRS, RA‐PRS, SLE‐PRS, DLBCL‐PRS, CLL‐PRS,
FL‐PRS, and MZL‐PRS, were calculated.
In each of the seven individual diseases, the mean PRS
was higher in cases than in controls as expected.
However, when the PRS of ADs were calculated in
NHL subtypes, the score was not significantly different
between cases and controls (Table S2). Similarly, when
PRS of NHL subtypes were calculated in ADs, the scores
were not significantly different between cases and
controls.
3.4 | Meta‐analysis
We combined each of the three ADs with each of the four
NHL GWAS in a series of 12 meta‐analyses to leverage
increased statistical power for the discovery of novel
SNPs associated with both diseases. In Table 3, we report
a list of SNPs that had statistically significant association
in a meta‐analysis of an AD with an NHL subtype, but
which did not meet the discovery threshold of signifi-
cance in the AD alone nor in the NHL subtype alone
(though they may not have met the strict definition of
genome‐wide significance threshold as defined in our
study, some of these hits had been carried forward by the
original authors to validation on additional samples and
subsequently been reported as significant in the original
discovery studies). SNPs that passed the analysis paper‐
wide significance threshold (the "paper‐wide threshold"
includes correction for total number of tests performed in
the total of 12 meta‐analyses reported in this paper) are
reported in Table 3. SNPs that passed a study‐wide
significance (after correction only for the total number of
SNPs in each meta‐analysis) are shown in Table S3.
3.5 | Diseasome
We reviewed 87 diseases (Table 4) for which sufficient
GWAS results were available in the public domain. Pair‐
wise proximities between these diseases were calculated
based on the degree of genome‐wide genetic overlap. A
graph of the proximity space reveals a cluster of 19
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TABLE 2 Overlap of SNPs between the three autoimmune diseases and the four non‐Hodgkin lymphoma subtypes
Analysis
Number of SNPs that were significant at
the threshold of 5e‐04
Number of SNPs with LD info
available in SNAP
Number of regions
based on LD
Number of SNPs that were significant after
correction (BH< 0.05)
SLE SNPs in DLBCL 2,472 1,718 389 2
DLBCL SNPs in SLE 524 334 190 3
SLE SNPs in CLL 2,471 1,718 389 5
CLL SNPs in SLE 895 625 240 4
SLE SNPs in FL 2,473 1,718 389 2
FL SNPs in SLE 558 393 206 5
SLE SNPs in MZL 2,462 1,718 389 4
MZL SNPs in SLE 390 259 168 6
RA SNPs in DLBCL 532 423 238 0
DLBCL SNPs in RA 504 425 190 1
RA SNPs in CLL 531 423 238 1
CLL SNPs in RA 844 724 232 1
RA SNPs in FL 532 423 238 3
FL SNPs in RA 471 395 199 4
RA SNPs in MZL 530 422 237 1
MZL SNPs in RA 351 283 148 2
MS SNPs in DLBCL 1,203 1,031 380 6
DLBCL SNPs in MS 366 329 195 6
MS SNPs in CLL 1,204 1,031 380 13
CLL SNPs in MS 659 586 244 14
MS SNPs in FL 1,203 1,031 380 11
FL SNPs in MS 402 369 203 12
MS SNPs in MZL 1,203 1,031 380 0
MZL SNPs in MS 253 219 152 1
Note: See supplementary table for details of each region.
Abbreviation: DLBCL, diffuse large B‐cell lymphoma; FL, follicular lymphoma; GWAS, genome‐wide association studies; LD, linkage disequilibrium; MS, multiple sclerosis; MZL, marginal zone lymphomas; RA,
rheumatoid arthritis; SLE, systemic lupus erythematosus; SNPs, single nucleotide polymorphisms.
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TABLE 3 SNPs that were significant in a meta‐analysis of an autoimmune disease with a non‐Hodgkin Lymphoma, but which did not meet the threshold of significance in the
autoimmune disease alone nor in the non‐Hodgkin Lymphoma alone
Study SNP p (AD)
OR
(AD) p (NHL)
OR
(NHL) p (Meta)
Corr. p
(Meta)
Paper corr. p
(Meta)
OR
(Meta) Chr Gene(s) of interest RA RDS
CLL vs. MS rs140522 3.85E‐06 0.91 1.18E‐05 0.86 6.49E‐11 2.99E‐05 4.32E‐04 0.90 22 ODF3B A 4
CLL vs. MS rs6793295 1.48E‐05 0.91 1.10E‐04 0.87 1.86E‐09 8.59E‐04 1.24E‐02 0.90 3 LRRC34 A 7
CLL vs. RA rs3731714 1.33E‐03 0.89 7.82E‐07 0.84 7.05E‐09 4.19E‐03 4.69E‐02 0.87 2 CASP10, PPIL3, CFLAR G 1d
DLBCL vs. MS rs2425752 1.70E‐06 0.91 1.10E‐02 0.92 5.10E‐09 2.35E‐03 3.39E‐02 0.91 20 NCOA5 A 1d
MZL vs. RA rs16947122 3.56E‐02 1.57 4.99E‐03 0.51 5.03E‐09 2.99E‐03 3.35E‐02 1.86 12 FBXW8, HRK, TESC C 5
MZL vs. RA rs1364229 1.73E‐04 1.30 1.66E‐04 0.72 1.66E‐10 9.86E‐05 1.10E‐03 1.35 16 CDH8 A 7
MZL vs. RA rs7192064 9.63E‐04 0.79 3.67E‐04 0.74 6.55E‐09 3.89E‐03 4.36E‐02 0.76 16 CDH8 G
MZL vs. RA rs2131402 2.50E‐04 0.77 3.67E‐04 0.74 1.51E‐09 8.97E‐04 1.01E‐02 0.75 16 CDH8 G 6
CLL vs. SLE rs1439112 1.80E‐07 0.85 3.84E‐03 1.10 7.09E‐09 4.33E‐03 4.72E‐02 0.88 2 MGAT5 A 4
CLL vs. SLE rs10936599 1.99E‐05 0.87 5.01E‐05 0.86 4.06E‐09 2.48E‐03 2.70E‐02 0.87 3 MYNN, ACTRT3, TERC,
LRRC34
C 5
CLL vs. SLE rs1317082 1.50E‐05 0.86 3.73E‐05 0.86 2.25E‐09 1.37E‐03 1.50E‐02 0.86 3 MYNN, ACTRT3, TERC,
LRRC34
A 6
CLL vs. SLE rs13069553 9.55E‐06 0.86 4.16E‐05 0.86 1.61E‐09 9.83E‐04 1.07E‐02 0.86 3 MYNN, ACTRT3, TERC,
LRRC34
A 5
CLL vs. SLE rs7621631 1.36E‐05 0.86 4.92E‐05 0.86 2.69E‐09 1.64E‐03 1.79E‐02 0.86 3 MYNN, ACTRT3, TERC,
LRRC34
C 7
CLL vs. SLE rs10069690 7.21E‐04 1.12 5.56E‐07 1.21 4.60E‐09 2.81E‐03 3.06E‐02 1.16 5 TERT T 5
Note: RA, risk allele. RDS, regulomeDB score. corr, Corrected for multiple hypothesis testing in a single meta‐analysis. Paper corr, corrected for multiple hypothesis testing in 12 meta‐analyses presented in this paper.
Abbreviations: AD, autoimmune diseases; CLL, chronic lymphocytic leukemia; DLBCL, diffuse large B‐cell lymphoma; MS, multiple sclerosis; MZL, marginal zone lymphomas; NHL, non‐Hodgkin lymphomas; RA,
rheumatoid arthritis; SLE, systemic lupus erythematosus.
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autoimmune diseases, a cluster of many of the 16
available solid cancers, and a cluster of the four NHLs,
which has closer common genetic risk overlap with
autoimmune diseases than with solid cancers in this two‐
dimensional projection (Figure 2, Panel 1). The mean
pair‐wise proximity metric between NHL subtypes and
autoimmune diseases was higher than the mean proxi-
mity between NHLs and solid cancers (0.0049 vs. 0.0023,
p = .0041, Figure 2, Panel 2). The mean pair‐wise
proximity between NHL variants and solid cancers was
higher than the mean proximity between NHL and all
other diseases (0.0023 vs. 0.0012, p = .00066, Figure 2,
Panel 2).
4 | DISCUSSION
In an effort to understand the association between AD
and NHL, we performed a series of analyses exploring the
genetic overlap between four NHL subtypes and three
ADs. We found that only a small number of risk loci
associated with NHL were also associated with AD risk,
and, conversely, that only a small number of AD risk loci
were associated with risk of the NHL subtypes studied.
Polygenic risk score analysis, which considers a large
number of genes and places less relative weight on the
top few genes, did not demonstrate the significant
genome‐wide polygenic overlap between any of the
NHL subtypes and any of the AD examined in this
study. Diseasome analysis, in contrast to polygenic risk
score analysis, places larger relative weight on a fewer
number of confirmed top genes. Diseasome analysis
revealed that the NHL subtypes tend to occupy a
common genetic risk neighborhood and that this
common neighborhood is closer to the group of ADs
than to the group of solid cancers. Thus, we conclude that
while few risk loci overlap between any pair of the
studied diseases, there is not enough genetic overlap
found in this study to explain an important proportion of
increased risk (less than one percent of disease risk
explained based on PRS analysis, Table S2).
Altogether, within the limitations inherent in the
available data our findings provide little evidence that
shared genetic risk factors are a major explanation for the
increased risk of malignant B‐cell lymphomas in patients
with autoimmune diseases, such as RA and SLE
(Baecklund et al., 2014). As this is also the case for
known environmental risk factors (Thun et al., 2017;
Deane et al., 2010) (Park et al., 2009; Belbasis et al., 2015;
Smedby & Ponzoni, 2017; Ekström et al., 2003; Bernatsky
et al., 2013), other mechanisms, such as inflammation
and chronic antigenic stimulation which increase B‐ and
T‐cell receptor rearrangement and B‐cell somatic hyper-
mutation, and/or AD treatment with immunosuppressive
or biologic therapy, seem likely to be more significant
contributors to the long‐standing association between the
two disease groups. The collective findings further
suggest that monitoring and managing inflammation or
other factors associated with the disease course as the
way to reducing the risk of malignant B‐cell lymphoma in
patients with AD (Baecklund et al., 2006).
A series of 12 meta‐analyses of the three individual
ADs with the four individual NHL subtypes demon-
strated seven regions which passed a genome‐wide
threshold of significance in the 12 meta‐analyses, which
would not have been discovered in the analysis of the
individual diseases due to limited power (Table 3). The
corresponding effect sizes were modest and total risk
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TABLE 4 Classification of immune and neoplastic diseases
from the diseasome
Autoimmune diseases Hematologic cancers
Alopecia areata (AR) Chronic lymphocytic
leukemia (CLL)
Ankylosing spondylitis (AS) Hodgkin lymphoma (HL)
Behcet's disease (Beh) Mutiple myeloma (MM)
Celiac disease (Cel) Diffuse large B‐cell
lymphoma (DLBCL)
Crohn's Disease (CD) Follicular lymphoma (FL)
Graves' Disease (GD) Marginal zone lymphoma
(MZL)
IgA glomerulonephritis (IgA)
Kawasaki disease (Kaw) Solid cancers
Multiple Sclerosis (MS) Basal cell carcinoma (BCC)
Primary biliary cirrhosis (PBC) Bladder carcinoma (BlC)
Psoriasis (Ps) Breast carcinoma (BrC)
Psoriatic arthritis (PsA) Central nervous system
cancer (CNS)
Rheumatoid arthritis (RA) Esophageal carcinoma
(EsC)
Sclerosing cholangitis (PSC) Lung Carcinoma (LuC)
Systemic lupus erythematosus
(SLE)
Lung adenocarcinoma
(LuA)
Systemic scleroderma (SS) Melanoma (Mel)
Type 1 diabetes mellitus (T1D) Neuroblastoma (NB)
Ulcerative colitis (UC) Ovarian carcinoma (OvC)
Vitiligo (Vit) Pancreatic carcinoma
(PaC)
Prostate carcinoma (PrC)
Renal cell carcinoma
(RCC)
Squamous cell carcinoma
(SCC)
Stomach carcinoma (StC)
Thyoid carcinoma (ThC)
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explained was low, however, the genes in these regions
are discussed in a Sopporting Text. In brief, the list
comprises genes involved in other cell proliferation and
specifically hematopoiesis, telomerase activity, and anti-
gen presentation (via, e.g., MGAT5). Many of these genes
have since been implicated in the ADs and NHLs
examined in this manuscript (as larger meta‐analyses of
the individual ADs and NHLs have been published),
which lends credibility to the present findings and
supports the potential advantage of the cross‐disease
meta‐analysis approach. Given the availability of studies
of the individual ADs and NHLs with larger sample sizes,
a repeat meta‐analysis would be possible.
There are noteworthy limitations to this study. First,
this is a post hoc secondary endpoint analysis; validation
in an independent data set would be required to confirm
the specific meta‐analysis findings, and a series of in vitro
and in vivo studies would be required to elucidate
mechanisms and imply causation. Some of the individual
NHL subtype GWAS were of relatively small sample size
and therefore, the statistical power in these analyses was
limited. A lack of whole‐exome coverage in a genome‐
wide study is another limitation; GWAS offers incom-
plete coverage and an imperfect view of the human
genome compared with newer methods. An expansion
cross‐disease analysis to larger datasets with greater
coverage would be of significant value. We completed 12
parallel meta‐analyses, which further imposed a limita-
tion on power; the multiple‐hypothesis correction for this
additional layer of hypothesis testing raised the threshold
of genome‐wide significance by one order of magnitude
and thus limited the power of new discovery. There were
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FIGURE 2 Panel 1. A graph of autoimmune diseases (purple), solid cancers (orange), hematologic cancers (white), and other diseases
(gray). The thickness of lines indicates greater levels of genetic overlap (proximity between diseases). Panel 2. The proximity between NHLs
and ADs (blue) is greater than the proximity between NHLs and solid cancers (orange), which is greater than the proximity between NHLs
and other diseases (green). ADs, autoimmune diseases; NHLs, non‐Hodgkin lymphomas
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many meta‐analyses hits that reached genome‐wide
significance but not paper‐wide significance; the vast
majority of these were the hits that have been confirmed
in recent published literature, suggesting that perhaps
future meta‐analyses should focus on individual disease
pairs, thus avoiding the additional limitation of parallel
meta‐analysis. The diseasome analysis was limited by an
inability to control for overlap in the control datasets of
the individual GWAS used to construct the diseasome. In
particular, for the diseases that were not classified as
NHL or AD, caution against overinterpretation of clusters
of diseases with shared GWAS controls is warranted.
The three ADs and the four NHL subtypes presented
here were selected because data were available and we
were able to create a relationship with the respective
consortia. It would be of value for future endeavors to
study other autoimmune diseases such as Sjögren's
syndrome and other lymphomas such as Hodgkin’s
lymphoma via a similar analysis pipeline, especially
given the observed epidemiologic links between those
other syndromes and the ones presented in this study.
5 | CONCLUSION
Within the limits of this GWAS‐based cross‐disease
analysis, we estimated that the shared genetic risk
between the three autoimmune diseases and four non‐
Hodgkin lymphoma subtypes is limited to a handful of
genes. This finding suggests that genetic etiology is not
the primary driver in the observed epidemiologic link
between AD and NHL, but rather the link may be driven
by nongenetic factors, such as chronic antigenic stimula-
tion and inflammation or immune‐modulating treatment.
A meta‐analysis of ADs with NHLs suggested new
candidate genes to explain the limited shared genetic
risk, with roles in the cell cycle, apoptosis, and telomere
length. Further meta‐analyses of genetic variants in
autoimmune diseases and lymphomas with larger data-
sets and deeper sequencing may provide further insight
into mechanisms common to the two groups of diseases.
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KEY MESSAGES
Within the limits of this GWAS‐based cross‐disease
analysis, the shared genetic risk between SLE, RA,
MS, and four common B‐cell NHL types was limited to
few weakly‐associated loci and explained little total
disease risk. Candidate genes with roles in the cell
cycle, apoptosis, and telomere length should be consid-
ered in future analyses of shared genetic susceptibility to
these conditions. Further meta‐analyses of genetic
variants in autoimmune diseases and lymphomas with
larger datasets and deeper sequencing may provide
further insight into mechanisms common to the two
groups of diseases.
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